All News

RheumNow Podcast square

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

d Jack Cush, MD

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
Vaccine2.jpg (keep)

Rare Risks Associated with BNT162b2 mRNA Covid-19 Vaccine

d Jack Cush, MD

The current NEJM reports that the use of the Pfizer mRNA vaccine (BNT162b2) demonstrated a very low risk for certain serious adverse events, including the risk of myocarditis (1 to 5 events per 100,000 persons). 

Read Article
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive RA. https://t.co/szl5L7DGJG https://t.co/vAXBNPxsWU

Links:

Dr. John Cush RheumNow ( View Tweet)
Arthritis clinic referrals divided into 2 cohorts: (A) 163 w/ MSK US before visit; (B) 109 without initial MSK US. MSK-US at 1st visit reduced time to Dx from mean 31 to 12 days (p< 0.01), # of clinic visits, & increased odds of inflamm Dx (47% vs 27%) https://t.co/FaXLBlRlxy

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters https://t.co/vT6185ycoG https://t.co/G14eLN2JkT

Links:

Dr. John Cush RheumNow ( View Tweet)
Si @DGlaucomflecken es el mejor se dice y ya está https://t.co/QzPyIe5gAA
Raruniente Raruniiente ( View Tweet)
New podcast available for download! COVID Marching Amidst the Madness https://t.co/xYzkw3zGRt https://t.co/gv45nVk9v5

Links:

Dr. John Cush RheumNow ( View Tweet)
In case you missed it: Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA). https://t.co/2YbLBsFedv https://t.co/OYMJ6Y54UF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

Oligoarticular vs. Polyarticular Psoriatic Arthritis https://t.co/lQVNdmWgMc https://t.co/ZjyDeYTLe2

Links:

Dr. John Cush RheumNow ( View Tweet)
We've got a new podcast up for you, focusing on all of this week's top stories on RheumNow. https://t.co/xYzkw3zGRt https://t.co/A75Cl3WYno

Links:

Dr. John Cush RheumNow ( View Tweet)
Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish study of 287 SLE pts shows rare risk of autoimmune liver disease. While 14% had persistent LFTs, only 2.8% dx w/ autoimmune hepatitis. 1.4-2.1% met criteria for primary biliary cholangitis. Both AIH & PBC AIH are overrepresented in SLE https://t.co/oc5SLJtycf

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 36 studies, 608 RA-Bronchiectasis among 8569 RA pts; pooled bronchiectasis prevalence in RA was 18.7% (range 15.5% to 20.7%). Risk factors: older age, longer RA duration, genetics (CFTR & HLA), undetectable MBL biomarker https://t.co/SSRoTCYkHf

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs https://t.co/XO4DPXwGQi https://t.co/S9E3yENfDF

Links:

Dr. John Cush RheumNow ( View Tweet)
Brazilian national study of 319 SLE & 251,800 nonSLE pts hospitalized with COVID-19 showed that SLE increases risk of death (RR 1.74) & poor outcomeS (RR 1.39). Having lupus doubled (RR 2.2) the risk of risk of death. https://t.co/8VJjdOEuzS

Links:

Dr. John Cush RheumNow ( View Tweet)

A prospective study evaluated the value and associations with morning stiffness (MS) in patients with clinically suspect arthralgia (CSA), and found that the presence of MS increases the odds of inflammation (as detected by CRP and MRI synovitis). https://t.co/4j5Zshn48a https://t.co/2UUguqpckF

Links:

Dr. John Cush RheumNow ( View Tweet)
2021–22 influenza season coincides with continued COVID infx & Sxs may be confused betw both. ACIP Influenza vaccination guidelines: 1. Annual flu vaccine rec to all >6mos; 2. COVID Vax can be given w/ Flu Vax; 3. give before Nov 2021 https://t.co/oIkl50GI0W

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparing COVID vaccines in rheum dz pts - 45 took J&J vax compared to 994 on mRNA vaccines. Detectable Ab responses lower w/ J&J (80% vs 92%, p=0.03) than mRNA vax. RTX, MMF & steroids significantly depressed Ab responses https://t.co/6ZJU8EVF5n

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×